Global Health Directorate, Indus Health Network, Karachi, Sindh, Pakistan.
Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, United States of America.
PLoS One. 2019 Aug 19;14(8):e0221485. doi: 10.1371/journal.pone.0221485. eCollection 2019.
To compare the diagnostic performance of the GenoType MRBDRplus assay with the gold standard phenotypic drug susceptibility testing in the detection of drug resistance among culture isolates obtained from patients in Karachi, Pakistan.
Mycobacterium tuberculosis isolates were obtained from 96 consecutive tuberculosis patients found to have resistance to isoniazid from two health centers in Karachi (January-November 2017). Isolates were tested for drug resistance against rifampin and isoniazid using the MTBDRplus assay. Results were compared with conventional drug-susceptibility testing and the frequency of specific mutations were reported.
The MTBDRplus assay had a sensitivity for rifampin resistance of 98.8% (95% CI: 93.4-100) and for isoniazid resistance of 90.6% (95% CI: 83.0-95.6). The MTBDRplus assay showed mutations in rpoB in 81 of the 96 (84.4%) isolates. Of the 87 isolates showing resistance to isoniazid via the MTBDRplus assay, 71 (74.0%) isolates had mutations in the katG gene only, 15 (15.6%) isolates had mutations in the inhA promoter region, and 1 (1.0%) showed mutations in both genes.
The GenoType MTBDRplus assay in Pakistan can identify subgroups at high-risk of having isolates with mutations in the katG and/or inhA genes. Understanding the local burden of these mutations have implications for local diagnostic and treatment guidelines.
比较 GenoType MRBDRplus 检测与金标准表型药敏试验在检测巴基斯坦卡拉奇患者培养分离物耐药性方面的诊断性能。
从卡拉奇的两个卫生中心(2017 年 1 月至 11 月)发现对异烟肼耐药的 96 例结核病患者中获得结核分枝杆菌分离物。使用 MTBDRplus 检测对利福平与异烟肼进行耐药性检测。将结果与传统药敏试验进行比较,并报告特定突变的频率。
MTBDRplus 检测对利福平耐药的敏感性为 98.8%(95%CI:93.4-100),对异烟肼耐药的敏感性为 90.6%(95%CI:83.0-95.6)。MTBDRplus 检测在 96 株分离物中发现 rpoB 突变 81 株(84.4%)。在 87 株通过 MTBDRplus 检测显示对异烟肼耐药的分离物中,katG 基因突变仅见于 71 株(74.0%),inhA 启动子区突变见于 15 株(15.6%),2 个基因均突变见于 1 株(1.0%)。
巴基斯坦的 GenoType MTBDRplus 检测可识别 katG 和/或 inhA 基因突变风险较高的亚组。了解这些突变的当地负担对当地诊断和治疗指南具有重要意义。